Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia

Sponsor
AUSL Romagna Rimini
Study ID
NCT04348448
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The study is configured as a retrospective and prospective observational study. The study will be multi-center and will involve all COVID-19 pneumonia patients treated with canakinumab administered subcutaneously.

Key Dates

Start date
Feb 1, 2020
Status verified
Apr 2020
Primary completion
May 1, 2020
Completion
Sep 1, 2020

Study Design

Enrollment
100 participants (actual)

Primary Outcome Measure

intensive care treatment [ Time Frame: 9 months ]

Related Studies